These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 16049458)

  • 1. Cancer: one step at a time.
    Mooney D
    Nature; 2005 Jul; 436(7050):468-9. PubMed ID: 16049458
    [No Abstract]   [Full Text] [Related]  

  • 2. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system.
    Sengupta S; Eavarone D; Capila I; Zhao G; Watson N; Kiziltepe T; Sasisekharan R
    Nature; 2005 Jul; 436(7050):568-72. PubMed ID: 16049491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative model for efficient temporal targeting of tumor cells and neovasculature.
    Kohandel M; Haselwandter CA; Kardar M; Sengupta S; Sivaloganathan S
    Comput Math Methods Med; 2011; 2011():790721. PubMed ID: 21461349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor.
    Li X; Wu M; Pan L; Shi J
    Int J Nanomedicine; 2016; 11():93-105. PubMed ID: 26766908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination drug delivery via multilamellar vesicles enables targeting of tumor cells and tumor vasculature.
    Liu Y; Kim YJ; Siriwon N; Rohrs JA; Yu Z; Wanga P
    Biotechnol Bioeng; 2018 Jun; 115(6):1403-1415. PubMed ID: 29457630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
    Dalal S; Burchill SA
    Eur J Cancer; 2009 Mar; 45(4):713-22. PubMed ID: 19136249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-angiogenesis: the challenges ahead.
    Mariani SM
    MedGenMed; 2003 Apr; 5(2):22. PubMed ID: 14603121
    [No Abstract]   [Full Text] [Related]  

  • 9. Nanotechnology for antiangiogenic cancer therapy.
    Kobayashi H; Lin PC
    Nanomedicine (Lond); 2006 Jun; 1(1):17-22. PubMed ID: 17716205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenesis drugs target specific cancers, mechanisms.
    Randal J
    J Natl Cancer Inst; 2000 Apr; 92(7):520-2. PubMed ID: 10749899
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting the tumor vascular compartment to improve conventional cancer therapy.
    Feron O
    Trends Pharmacol Sci; 2004 Oct; 25(10):536-42. PubMed ID: 15380938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents target existing tumor vasculature.
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):303. PubMed ID: 20235388
    [No Abstract]   [Full Text] [Related]  

  • 13. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 14. [Bevacizumab].
    Taéron C
    Rev Infirm; 2009; (147):46-8. PubMed ID: 19317091
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimizing the delivery of cancer drugs that block angiogenesis.
    Cao Y; Langer R
    Sci Transl Med; 2010 Jan; 2(15):15ps3. PubMed ID: 20371469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metronomic chemotherapy: Back to the future!
    André N; Padovani L; Verschuur A
    Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular normalization: a real benefit?
    Ribatti D
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):275-8. PubMed ID: 21638121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis. A boost for tumor starvation.
    Marx J
    Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
    [No Abstract]   [Full Text] [Related]  

  • 19. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiangiogenesis: new frontiers in therapeutic development.
    LaMontagne KR
    Angiogenesis; 2005; 8(4):285-7. PubMed ID: 16400519
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.